{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:35:40Z","timestamp":1790534140494,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","award":["591704"],"award-info":[{"award-number":["591704"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MandarinoFoundationGift"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00280-021-04309-y","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T06:02:26Z","timestamp":1623736946000},"page":"607-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma"],"prefix":"10.1007","volume":"88","author":[{"given":"Chad R.","family":"Schultz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-8560","authenticated-orcid":false,"given":"Andr\u00e9 S.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"issue":"9579","key":"4309_CR1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"JM Maris","year":"2007","unstructured":"Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579):2106\u20132120","journal-title":"Lancet"},{"issue":"3","key":"4309_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2529","volume":"45","author":"TJ Pugh","year":"2013","unstructured":"Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet 45(3):279\u2013284. https:\/\/doi.org\/10.1038\/ng.2529","journal-title":"Nat Genet"},{"issue":"23","key":"4309_CR3","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202\u20132211. https:\/\/doi.org\/10.1056\/NEJMra0804577","journal-title":"N Engl J Med"},{"key":"4309_CR4","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","volume":"2","author":"KK Matthay","year":"2016","unstructured":"Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078. https:\/\/doi.org\/10.1038\/nrdp.2016.78","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4309_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","volume":"3","author":"GM Brodeur","year":"2003","unstructured":"Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203\u2013216","journal-title":"Nat Rev Cancer"},{"key":"4309_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2020.05.010","volume":"136","author":"L Moreno","year":"2020","unstructured":"Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav S, Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJ (2020) Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from innovative therapies for children with cancer and international society of paediatric oncology Europe neuroblastoma. Eur J Cancer 136:52\u201368. https:\/\/doi.org\/10.1016\/j.ejca.2020.05.010","journal-title":"Eur J Cancer"},{"issue":"14","key":"4309_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children\u2019s Oncology G (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324\u20131334. https:\/\/doi.org\/10.1056\/NEJMoa0911123","journal-title":"N Engl J Med"},{"issue":"8","key":"4309_CR8","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","volume":"27","author":"AL Yu","year":"2021","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM (2021) Long-term follow-up of a phase III study of ch14.18 (Dinutuximab) + Cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res 27(8):2179\u20132189. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3909","journal-title":"Clin Cancer Res"},{"issue":"29","key":"4309_CR9","doi-asserted-by":"publisher","first-page":"14904","DOI":"10.1074\/jbc.R116.731661","volume":"291","author":"AE Pegg","year":"2016","unstructured":"Pegg AE (2016) Functions of polyamines in mammals. J Biol Chem 291(29):14904\u201314912. https:\/\/doi.org\/10.1074\/jbc.R116.731661","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"4309_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1042\/BST0350295","volume":"35","author":"AE Pegg","year":"2007","unstructured":"Pegg AE, Feith DJ (2007) Polyamines and neoplastic growth. Biochem Soc Trans 35(Pt 2):295\u2013299. https:\/\/doi.org\/10.1042\/BST0350295","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"4309_CR11","doi-asserted-by":"publisher","first-page":"C212","DOI":"10.1152\/ajpcell.1982.243.5.C212","volume":"243","author":"AE Pegg","year":"1982","unstructured":"Pegg AE, McCann PP (1982) Polyamine metabolism and function. Am J Physiol 243(5):C212\u2013C221","journal-title":"Am J Physiol"},{"issue":"5","key":"4309_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrd2243","volume":"6","author":"RA Casero Jr","year":"2007","unstructured":"Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6(5):373\u2013390","journal-title":"Nat Rev Drug Discov"},{"key":"4309_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","volume":"18","author":"RA Casero Jr","year":"2018","unstructured":"Casero RA Jr, Murray Stewart T, Pegg AE (2018) Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer 18:681\u2013695. https:\/\/doi.org\/10.1038\/s41568-018-0050-3","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4309_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrc1454","volume":"4","author":"EW Gerner","year":"2004","unstructured":"Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4(10):781\u2013792","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4309_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/2159-8290.CD-17-0273","volume":"8","author":"DS Rickman","year":"2018","unstructured":"Rickman DS, Schulte JH, Eilers M (2018) The expanding world of N-MYC-driven tumors. Cancer Discov 8(2):150\u2013163. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0273","journal-title":"Cancer Discov"},{"issue":"2","key":"4309_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/sj.onc.1201939","volume":"17","author":"T Ben-Yosef","year":"1998","unstructured":"Ben-Yosef T, Yanuka O, Halle D, Benvenisty N (1998) Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 17(2):165\u2013171","journal-title":"Oncogene"},{"issue":"2","key":"4309_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.canlet.2010.01.015","volume":"293","author":"E Bell","year":"2010","unstructured":"Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA (2010) MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 293(2):144\u2013157. https:\/\/doi.org\/10.1016\/j.canlet.2010.01.015","journal-title":"Cancer Lett"},{"issue":"5","key":"4309_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ccr.2005.03.036","volume":"7","author":"JA Nilsson","year":"2005","unstructured":"Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL (2005) Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7(5):433\u2013444","journal-title":"Cancer Cell"},{"key":"4309_CR19","first-page":"445","volume":"182","author":"C Bello-Fernandez","year":"1992","unstructured":"Bello-Fernandez C, Cleveland JL (1992) c-myc transactivates the ornithine decarboxylase gene. Curr Top Microbiol Immunol 182:445\u2013452","journal-title":"Curr Top Microbiol Immunol"},{"issue":"16","key":"4309_CR20","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.1073\/pnas.90.16.7804","volume":"90","author":"C Bello-Fernandez","year":"1993","unstructured":"Bello-Fernandez C, Packham G, Cleveland JL (1993) The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 90(16):7804\u20137808","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"4309_CR21","first-page":"803","volume":"13","author":"W Lutz","year":"1996","unstructured":"Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13(4):803\u2013812","journal-title":"Oncogene"},{"issue":"12","key":"4309_CR22","first-page":"371","volume":"63","author":"AS Bachmann","year":"2004","unstructured":"Bachmann AS (2004) The role of polyamines in human cancer: prospects for drug combination therapies. Hawaii Med J 63(12):371\u2013374","journal-title":"Hawaii Med J"},{"issue":"36","key":"4309_CR23","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/sj.onc.1208808","volume":"24","author":"CJ Wallick","year":"2005","unstructured":"Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, Seki JA, Pegg AE, Byus CV, Bachmann AS (2005) Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24(36):5606\u20135618","journal-title":"Oncogene"},{"issue":"48","key":"4309_CR24","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1074\/jbc.TM118.003336","volume":"293","author":"AS Bachmann","year":"2018","unstructured":"Bachmann AS, Geerts D (2018) Polyamine synthesis as a target of MYC oncogenes. J Biol Chem 293(48):18757\u201318769. https:\/\/doi.org\/10.1074\/jbc.TM118.003336","journal-title":"J Biol Chem"},{"key":"4309_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-94-007-2418-1_9","volume-title":"Pediatric cancer, neuroblastoma: diagnosis, therapy, and prognosis","author":"AS Bachmann","year":"2012","unstructured":"Bachmann AS, Geerts D, Sholler G (2012) Neuroblastoma: ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. In: Hayat MA (ed) Pediatric cancer, neuroblastoma: diagnosis, therapy, and prognosis, vol 1. Springer, pp 91\u2013103"},{"key":"4309_CR26","first-page":"257","volume-title":"Polyamine drug discovery","author":"AS Bachmann","year":"2012","unstructured":"Bachmann AS, Levin VA (2012) Clinical applications of polyamine-based therapeutics. In: Woster PM, Casero RA Jr (eds) Polyamine drug discovery, vol 17. Royal Society of Chemistry, pp 257\u2013276"},{"issue":"9","key":"4309_CR27","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/ijc.25074","volume":"126","author":"D Geerts","year":"2010","unstructured":"Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS (2010) The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 126(9):2012\u20132024. https:\/\/doi.org\/10.1002\/ijc.25074","journal-title":"Int J Cancer"},{"issue":"4","key":"4309_CR28","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3892\/ijo.2013.1835","volume":"42","author":"DL Koomoa","year":"2013","unstructured":"Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS (2013) DFMO\/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 42(4):1219\u20131228. https:\/\/doi.org\/10.3892\/ijo.2013.1835","journal-title":"Int J Oncol"},{"issue":"23","key":"4309_CR29","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.1158\/0008-5472.CAN-08-1865","volume":"68","author":"DL Koomoa","year":"2008","unstructured":"Koomoa DL, Yco LP, Borsics T, Wallick CJ, Bachmann AS (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt\/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68(23):9825\u20139831","journal-title":"Cancer Res"},{"issue":"6","key":"4309_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ijc.28139","volume":"133","author":"K Samal","year":"2013","unstructured":"Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Sholler G (2013) AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer 133(6):1323\u20131333. https:\/\/doi.org\/10.1002\/ijc.28139","journal-title":"Int J Cancer"},{"issue":"3","key":"4309_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3978\/j.issn.2224-4336.2015.04.06","volume":"4","author":"H Bassiri","year":"2015","unstructured":"Bassiri H, Benavides A, Haber M, Gilmour SK, Norris MD, Hogarty MD (2015) Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Transl Pediatr 4(3):226\u2013238. https:\/\/doi.org\/10.3978\/j.issn.2224-4336.2015.04.06","journal-title":"Transl Pediatr"},{"issue":"23","key":"4309_CR32","doi-asserted-by":"publisher","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","volume":"68","author":"MD Hogarty","year":"2008","unstructured":"Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M (2008) ODC1 Is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68(23):9735\u20139745","journal-title":"Cancer Res"},{"issue":"9683","key":"4309_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","volume":"374","author":"G Priotto","year":"2009","unstructured":"Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374(9683):56\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(09)61117-X","journal-title":"Lancet"},{"issue":"2","key":"4309_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/cid\/cis886","volume":"56","author":"E Alirol","year":"2013","unstructured":"Alirol E, Schrumpf D, Amici Heradi J, Riedel A, de Patoul C, Quere M, Chappuis F (2013) Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clin Infect Dis 56(2):195\u2013203. https:\/\/doi.org\/10.1093\/cid\/cis886","journal-title":"Clin Infect Dis"},{"key":"4309_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis886","author":"E Alirol","year":"2012","unstructured":"Alirol E, Shrumpf D, Heradi JA, Riedel A, de Patoul C, Quere M, Chappuis F (2012) Nifurtimox-Eflornithine Combination Therapy (NECT) for second-stage gambiense human African trypanosomiasis: MSF experience in the Democratic Republic of the Congo. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/cis886","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4309_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00726-007-0537-9","volume":"33","author":"O Heby","year":"2007","unstructured":"Heby O, Persson L, Rentala M (2007) Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas\u2019 disease, and leishmaniasis. Amino Acids 33(2):359\u2013366","journal-title":"Amino Acids"},{"issue":"5","key":"4309_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1529-8019.2008.00215.x","volume":"21","author":"U Blume-Peytavi","year":"2008","unstructured":"Blume-Peytavi U, Hahn S (2008) Medical treatment of hirsutism. Dermatol Ther 21(5):329\u2013339. https:\/\/doi.org\/10.1111\/j.1529-8019.2008.00215.x","journal-title":"Dermatol Ther"},{"issue":"9","key":"4309_CR38","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1365-4632.2007.03270.x","volume":"46","author":"J Jackson","year":"2007","unstructured":"Jackson J, Caro JJ, Caro G, Garfield F, Huber F, Zhou W, Lin CS, Shander D, Schrode K, Eflornithine HSG (2007) The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. Int J Dermatol 46(9):976\u2013981. https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03270.x","journal-title":"Int J Dermatol"},{"issue":"5","key":"4309_CR39","doi-asserted-by":"publisher","first-page":"e0127246","DOI":"10.1371\/journal.pone.0127246","volume":"10","author":"GL Saulnier Sholler","year":"2015","unstructured":"Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS (2015) A phase I trial of DFMO targeting polyamine addiction in patients with relapsed\/refractory neuroblastoma. PLoS ONE 10(5):e0127246. https:\/\/doi.org\/10.1371\/journal.pone.0127246","journal-title":"PLoS ONE"},{"issue":"11","key":"4309_CR40","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1002\/ijc.33044","volume":"147","author":"EC Lewis","year":"2020","unstructured":"Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL (2020) A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer 147(11):3152\u20133159. https:\/\/doi.org\/10.1002\/ijc.33044","journal-title":"Int J Cancer"},{"key":"4309_CR41","first-page":"147","volume":"20","author":"GJ Kelloff","year":"1994","unstructured":"Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG et al (1994) Clinical development plan: 2-difluoromethylornithine (DFMO). J Cell Biochem Suppl 20:147\u2013165","journal-title":"J Cell Biochem Suppl"},{"issue":"10","key":"4309_CR42","first-page":"3850","volume":"6","author":"PP Carbone","year":"2000","unstructured":"Carbone PP, Douglas JA, Thomas J, Tutsch K, Pomplun M, Hamielec M, Pauk D (2000) Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine. Clin Cancer Res 6(10):3850\u20133854","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4309_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.apsb.2016.07.013","volume":"6","author":"J Yin","year":"2016","unstructured":"Yin J, Wang J (2016) Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B 6(5):363\u2013373. https:\/\/doi.org\/10.1016\/j.apsb.2016.07.013","journal-title":"Acta Pharm Sin B"},{"key":"4309_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0021-9673(01)93283-2","volume":"511","author":"SC Minocha","year":"1990","unstructured":"Minocha SC, Minocha R, Robie CA (1990) High-performance liquid chromatographic method for the determination of dansyl-polyamines. J Chromatogr 511:177\u2013183","journal-title":"J Chromatogr"},{"issue":"14","key":"4309_CR45","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1042\/BCJ20190294","volume":"476","author":"CR Schultz","year":"2019","unstructured":"Schultz CR, Bupp CP, Rajasekaran S, Bachmann AS (2019) Biochemical features of primary cells from a pediatric patient with a gain-of-function ODC1 genetic mutation. Biochem J 476(14):2047\u20132057. https:\/\/doi.org\/10.1042\/BCJ20190294","journal-title":"Biochem J"},{"issue":"2","key":"4309_CR46","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1042\/BCJ20170597","volume":"475","author":"CR Schultz","year":"2018","unstructured":"Schultz CR, Geerts D, Mooney M, El-Khawaja R, Koster J, Bachmann AS (2018) Synergistic drug combination GC7\/DFMO suppresses hypusine\/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma. Biochem J 475(2):531\u2013545. https:\/\/doi.org\/10.1042\/BCJ20170597","journal-title":"Biochem J"},{"issue":"12","key":"4309_CR47","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1535-7163.MCT-19-0385","volume":"18","author":"TH Nguyen","year":"2019","unstructured":"Nguyen TH, Koneru B, Wei SJ, Chen WH, Makena MR, Urias E, Kang MH, Reynolds CP (2019) Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2-expressing neuroblastoma preclinical models. Mol Cancer Ther 18(12):2270\u20132282. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0385","journal-title":"Mol Cancer Ther"},{"key":"4309_CR48","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1021\/ja00476a050","volume":"100","author":"BW Metcalf","year":"1978","unstructured":"Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogs. J Am Chem Soc 100:2551\u20132553","journal-title":"J Am Chem Soc"},{"issue":"1","key":"4309_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2015.2411","volume":"37","author":"MU Ahmed","year":"2016","unstructured":"Ahmed MU, Bennett DJ, Hsieh TC, Doonan BB, Ahmed S, Wu JM (2016) Repositioning of drugs using open-access data portal DTome: a test case with probenecid (review). Int J Mol Med 37(1):3\u201310. https:\/\/doi.org\/10.3892\/ijmm.2015.2411","journal-title":"Int J Mol Med"},{"issue":"9","key":"4309_CR50","first-page":"3705","volume":"6","author":"FM Sirotnak","year":"2000","unstructured":"Sirotnak FM, Wendel HG, Bornmann WG, Tong WP, Miller VA, Scher HI, Kris MG (2000) Co-administration of probenecid, an inhibitor of a cMOAT\/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 6(9):3705\u20133712","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4309_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","volume":"36","author":"KC Cundy","year":"1999","unstructured":"Cundy KC (1999) Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36(2):127\u2013143. https:\/\/doi.org\/10.2165\/00003088-199936020-00004","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4309_CR52","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1128\/AAC.00047-08","volume":"52","author":"M Holodniy","year":"2008","unstructured":"Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N, Deyton LR (2008) Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 52(9):3013\u20133021. https:\/\/doi.org\/10.1128\/AAC.00047-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4309_CR53","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/bcp.13728","volume":"84","author":"G Latkovskis","year":"2018","unstructured":"Latkovskis G, Makarova E, Mazule M, Bondare L, Hartmane D, Cirule H, Grinberga S, Erglis A, Liepinsh E, Dambrova M (2018) Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine-N-oxide. Br J Clin Pharmacol 84(11):2634\u20132644. https:\/\/doi.org\/10.1111\/bcp.13728","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"4309_CR54","first-page":"3944","volume":"41","author":"FM Sirotnak","year":"1981","unstructured":"Sirotnak FM, Moccio DM, Hancock CH, Young CW (1981) Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport. Cancer Res 41(10):3944\u20133949","journal-title":"Cancer Res"},{"issue":"1","key":"4309_CR55","first-page":"89","volume":"284","author":"WC Zamboni","year":"1998","unstructured":"Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF (1998) Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284(1):89\u201394","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"4309_CR56","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1128\/AAC.01063-15","volume":"59","author":"J Rullas","year":"2015","unstructured":"Rullas J, Dhar N, McKinney JD, Garcia-Perez A, Lelievre J, Diacon AH, Hugonnet JE, Arthur M, Angulo-Barturen I, Barros-Aguirre D, Ballell L (2015) Combinations of beta-lactam antibiotics currently in clinical trials are efficacious in a DHP-I-deficient mouse model of tuberculosis infection. Antimicrob Agents Chemother 59(8):4997\u20134999. https:\/\/doi.org\/10.1128\/AAC.01063-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4309_CR57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/cts.12486","volume":"10","author":"MM Posada","year":"2017","unstructured":"Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM (2017) Prediction of transporter-mediated drug-drug interactions for baricitinib. Clin Transl Sci 10(6):509\u2013519. https:\/\/doi.org\/10.1111\/cts.12486","journal-title":"Clin Transl Sci"},{"key":"4309_CR58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fnagi.2018.00060","volume":"10","author":"J Alber","year":"2018","unstructured":"Alber J, McGarry K, Noto RB, Snyder PJ (2018) Use of eflornithine (DFMO) in the treatment of early Alzheimer\u2019s disease: a compassionate use single-case study. Front Aging Neurosci 10:60. https:\/\/doi.org\/10.3389\/fnagi.2018.00060","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"4309_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/0008-5472.CAN-08-2968","volume":"69","author":"RJ Rounbehler","year":"2009","unstructured":"Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL (2009) Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69(2):547\u2013553","journal-title":"Cancer Res"},{"issue":"1","key":"4309_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.18632\/oncotarget.2768","volume":"6","author":"AM Lozier","year":"2015","unstructured":"Lozier AM, Rich ME, Grawe AP, Peck AS, Zhao P, Chang AT, Bond JP, Sholler GS (2015) Targeting ornithine decarboxylase reverses the LIN28\/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget 6(1):196\u2013206","journal-title":"Oncotarget"},{"issue":"12","key":"4309_CR61","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1002\/ajmg.a.40523","volume":"176","author":"CP Bupp","year":"2018","unstructured":"Bupp CP, Schultz CR, Uhl KL, Rajasekaran S, Bachmann AS (2018) Novel de novo pathogenic variant in the ODC1 gene in a girl with developmental delay, alopecia, and dysmorphic features. Am J Med Genet A 176(12):2548\u20132553. https:\/\/doi.org\/10.1002\/ajmg.a.40523","journal-title":"Am J Med Genet A"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04309-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04309-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04309-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T06:03:15Z","timestamp":1629093795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04309-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4309"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04309-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ASB is the sole inventor of U.S. patent (US 9,072,778) issued on July 7, 2015 entitled \u201cTreatment Regimen for N-Myc, C-Myc, and L-Myc amplified and overexpressed tumors\u201d. ASB was an oncology consultant for Lodo Therapeutics (New York, NY). No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}